Search

Your search keyword '"Kaplan, David E."' showing total 2,695 results
Start Over Author "Kaplan, David E."
2,695 results on '"Kaplan, David E."'

202. Genome-wide association study and replication of liver enzyme loci

Author

Pazoki, Raha, Vujkovic, Marijana, Elliott, Joshua, Evangelou, Evangelos, Gill, Dipender, Ghanbari, Mohsen, Van der Most, Peter J., Pinto, Rui Climaco, Wielscher, Matthias, Farlik, Matthias, Zuber, Verena, de Knegt, Robert J., Snieder, Harold, Uitterlinden, Andre G., Lynch, Julie A., Jiang, Xiyun, Said, Saredo, Kaplan, David E., Lee, Kyung Min, Serper, Marina, Carr, Rotonya M., Tsao, Philip S., Atkinson, Stephen R., Dehghan, Abbas, Tzoulaki, Ioanna, Ikram, Arfan, Herzig, Karl-Heinz, Jarvelin, Marjo-Riitta, Alizadeh, Behrooz Z., O'Don-Nell, Christopher J., Saleheen, Danish, Voight, Benjamin F., Chang, Kyong-Mi, Thursz, Mark R., Elliott, Paul, Life Course Epidemiology (LCE), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Published
2022

211. sj-docx-1-tag-10.1177_17562848221100106 – Supplemental material for Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study

Author

Howell, Jessica, Samani, Amit, Mannan, Binish, Hajiev, Saur, Motedayen Aval, Leila, Abdelmalak, Rebecca, Tam, Vincent C., Bettinger, Dominik, Thimme, Robert, Taddei, Tamar H., Kaplan, David E., Seidensticker, Max, and Sharma, Rohini

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tag-10.1177_17562848221100106 for Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study by Jessica Howell, Amit Samani, Binish Mannan, Saur Hajiev, Leila Motedayen Aval, Rebecca Abdelmalak, Vincent C. Tam, Dominik Bettinger, Robert Thimme, Tamar H. Taddei, David E. Kaplan, Max Seidensticker and Rohini Sharma in Therapeutic Advances in Gastroenterology

Published
2022
Full Text
View/download PDF

217. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study

Author

Howell, Jessica, primary, Samani, Amit, additional, Mannan, Binish, additional, Hajiev, Saur, additional, Motedayen Aval, Leila, additional, Abdelmalak, Rebecca, additional, Tam, Vincent C., additional, Bettinger, Dominik, additional, Thimme, Robert, additional, Taddei, Tamar H., additional, Kaplan, David E., additional, Seidensticker, Max, additional, and Sharma, Rohini, additional

Published
2022
Full Text
View/download PDF

222. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis.

Author

Chapin, William J., Hwang, Wei‐Ting, Karasic, Thomas B., McCarthy, Anne Marie, and Kaplan, David E.

Subjects
NIVOLUMAB, SORAFENIB, HEPATOCELLULAR carcinoma, PROPORTIONAL hazards models, CIRRHOSIS of the liver
Abstract

Background: Patients with decompensated cirrhosis are excluded or underrepresented in clinical trials of systemic therapies for hepatocellular carcinoma (HCC) and comparisons of available therapies are lacking. We aimed to compare overall survival for patients with HCC and Child‐Pugh B cirrhosis treated with nivolumab or sorafenib as first systemic treatment. Methods: We performed a retrospective cohort study in patients with HCC and Child‐Pugh B cirrhosis treated at Veterans Affairs medical centers to compare overall survival, adverse events, and reason for discontinuation of therapy between patients treated with nivolumab or sorafenib as first systemic treatment. All statistical tests were 2‐sided. Results: Of those meeting inclusion criteria, 431 patients were treated with sorafenib and 79 with nivolumab. Median OS was 4.0 months (95% CI 3.5–4.8) in the sorafenib cohort and 5.0 months (95% CI 3.3–6.8) in the nivolumab cohort. In the multivariable Cox proportional hazards model, nivolumab was associated with a significantly reduced hazard of death compared to sorafenib (HR 0.69; 95% CI 0.52–0.91; p = 0.008). In a secondary analysis using propensity score methods, results did not reach statistical significance (HR 0.77; 95% CI 0.55–1.06; p = 0.11). Treatment was discontinued due to toxicity in 12% of patients receiving nivolumab compared to 36% receiving sorafenib (p = 0.001). Conclusion: In patients with HCC and Child‐Pugh B cirrhosis, nivolumab treatment may be associated with improved overall survival and improved tolerability compared to sorafenib and should be considered for the first systemic treatment in this population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

224. External Validation of the VOCAL-Penn Cirrhosis Surgical Risk Score in Two Large, Independent Health Systems

Author

Mahmud, Nadim, Fricker, Zachary, Panchal, Sarjukumar, Lewis, James D., Goldberg, David S., and Kaplan, David E.

Subjects
body regions, End Stage Liver Disease, Liver Cirrhosis, Risk Factors, Humans, Prognosis, Severity of Illness Index, Article, Liver Transplantation, Retrospective Studies
Abstract

Cirrhosis poses an increased risk of postoperative mortality, yet it remains challenging to accurately risk stratify patients in clinical practice. The VOCAL-Penn cirrhosis surgical risk score was recently developed and internally validated in the national Veterans Affairs health system; however, to date this score has not been evaluated in independent cohorts. The goal of this study was to compare the predictive performance of the VOCAL-Penn to the Mayo risk, Model for End-Stage Liver Disease (MELD), and MELD-sodium (MELD-Na) scores in 2 large health systems. We performed a retrospective cohort study of patients with cirrhosis undergoing surgical procedures of interest at the Beth Israel Deaconess Medical Center or University of Pennsylvania Health System from January 1, 2008, to October 1, 2015. The outcomes of interest were 30-day and 90-day postoperative mortality. Concordance statistics (C-statistics), calibration curves, Brier scores, and the index of prediction accuracy (IPA) were compared for each predictive model. A total of 855 surgical procedures were identified. The VOCAL-Penn score had the numerically highest C-statistic for 90-day postoperative mortality (eg, 0.82 versus 0.79 Mayo versus 0.78 MELD-Na versus 0.79 MELD), although differences were not statistically significant. Calibrations were excellent for the VOCAL-Penn, MELD, and MELD-Na; however, the Mayo score consistently overestimated risk. The VOCAL-Penn had the lowest Brier score and highest IPA at both time points, suggesting superior overall predictive model performance. In subgroup analyses of patients with higher MELD scores, the VOCAL-Penn had significantly higher C-statistics compared with the MELD and MELD-Na. The VOCAL-Penn score (www.vocalpennscore.com) has excellent discrimination and calibration for postoperative mortality among diverse patients with cirrhosis. Overall performance is superior to the Mayo, MELD, and MELD-Na scores. In contrast to the MELD/MELD-Na, the VOCAL-Penn retains excellent discrimination among patients with higher MELD scores.

Published
2021

228. Dark energy radiation

Author

Berghaus, Kim V., primary, Graham, Peter W., additional, Kaplan, David E., additional, Moore, Guy D., additional, and Rajendran, Surjeet, additional

Published
2021
Full Text
View/download PDF

230. REPLY

Author

John, Binu V., primary, Deng, Yangyang, additional, Martin, Paul, additional, Levy, Cynthia, additional, Taddei, Tamar H., additional, Kaplan, David E., additional, and Dahman, Bassam, additional

Published
2021
Full Text
View/download PDF

250. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis

Author

John, Binu V., primary, Khakoo, Nidah S., additional, Schwartz, Kaley B., additional, Aitchenson, Gabriella, additional, Levy, Cynthia, additional, Dahman, Bassam, additional, Deng, Yangyang, additional, Goldberg, David S., additional, Martin, Paul, additional, Kaplan, David E., additional, and Taddei, Tamar H., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results